November 24, 2014—A leading hospital group purchasing organization and 16 prominent health care institutions asked Genentech in an open letter in The New York Times yesterday to reverse its “ill-advised decision” to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the more expensive specialty distribution channel.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)